Corrections
In our original manuscript [1], the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be:
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.
Also the title of our original manuscript ‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion’ is also incorrect. The title should read:‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition’.
Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
All authors read and approved the final manuscript.
Contributor Information
Erika Hamilton, Email: erika.hamilton2@dm.duke.edu.
Kimberly Blackwell, Email: black034@mc.duke.edu.
Amy C Hobeika, Email: amy.hobeika@duke.edu.
Timothy M Clay, Email: timothy.m.clay@gskbio.com.
Gloria Broadwater, Email: gloria.broadwater@duke.edu.
Xiu-Rong Ren, Email: xiu-rong.ren@duke.edu.
Wei Chen, Email: wei.chen@duke.edu.
Henry Castro, Email: HENRY.X.CASTRO@GSKBIO.COM.
Frederic Lehmann, Email: FREDERIC.F.LEHMANN@GSKBIO.COM.
Neil Spector, Email: neil.spector@duke.edu.
Junping Wei, Email: junping.wei@duke.edu.
Takuya Osada, Email: osada001@mc.duke.edu.
H Kim Lyerly, Email: lyerl001@mc.duke.edu.
Michael A Morse, Email: michael.morse@duke.edu.
References
- Hamilton. Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion. J Transl Med. 2012;10:28. doi: 10.1186/1479-5876-10-28. [DOI] [PMC free article] [PubMed] [Google Scholar]